“I have a tremendous amount of confidence in our team’s ability to continue to bring new technologies to market,
be those innovations to advance our existing platforms, like the HeartMate II, or entirely new pump platforms
like the HeartMate III.” Gary Burbach, President and CEO

As we look ahead, Thoratec is committed to furthering the use of MCS therapies to achieve dramatically improved outcomes for a broader range of patients. A major priority for the company is continuing our industry leadership in technology innovation. We will build upon our successes with strategic programs focused on advancing our HeartMate II platform, cross-platform initiatives, and the development of future pump platforms, such as the HeartMate III, the HeartMate X, and the Percutaneous Heart Pump (PHP).

To meet the expanding needs of patients, including those in earlier stage heart failure, Thoratec will drive cross-platform innovation that includes tools to facilitate an easier, less invasive implantation; technology to reduce the risk of infection; and a fully implantable system. Our focus is on the continual development of treatment options that will deliver improved outcomes, expanded choice, and enhanced quality of life for the patients that we serve.

In this new era of heart failure treatment, Thoratec’s medical technologies will help make it possible for thousands of people to resume everyday activities, spend meaningful time with their loved ones, and live better, longer.

Thoratec: Life Restored.